Zynerba Pharmaceuticals Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Zynerba Pharmaceuticals stock.
View analyst ratings for Zynerba Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Zynerba Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zynerba Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Zynerba Pharmaceuticals saw a drop in short interest in the month of February. As of February 12th, there was short interest totaling 3,200,000 shares, a drop of 22.5% from the January 28th total of 4,130,000 shares. Based on an average trading volume of 4,870,000 shares, the days-to-cover ratio is currently 0.7 days.
View Zynerba Pharmaceuticals' Short Interest.

Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Zynerba Pharmaceuticals.

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) posted its earnings results on Monday, November, 9th. The company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.12.
View Zynerba Pharmaceuticals' earnings history.

Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZYNE stock has increased by 19.8% and is now trading at $4.66.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 12 month price objectives for Zynerba Pharmaceuticals' stock. Their forecasts range from $8.00 to $26.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $15.40 in the next twelve months. This suggests a possible upside of 230.5% from the stock's current price.
View analysts' price targets for Zynerba Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Zynerba Pharmaceuticals include Relmada Therapeutics (RLMD), Bicycle Therapeutics (BCYC), Summit Therapeutics (SMMT), AC Immune (ACIU), Altimmune (ALT), Magenta Therapeutics (MGTA), Applied Therapeutics (APLT), Syros Pharmaceuticals (SYRS), Urovant Sciences (UROV), Spectrum Pharmaceuticals (SPPI), Viking Therapeutics (VKTX), Affimed (AFMD), BeyondSpring (BYSI), Neoleukin Therapeutics (NLTX) and Crinetics Pharmaceuticals (CRNX).
View all of ZYNE's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).

(ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Zynerba Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include ETF Managers Group LLC (6.16%), AdvisorShares Investments LLC (2.07%), BlackRock Inc. (1.38%), JPMorgan Chase & Co. (0.78%), Renaissance Technologies LLC (0.49%) and Penserra Capital Management LLC (0.44%).
View institutional ownership trends for Zynerba Pharmaceuticals.

ZYNE stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, and Northern Trust Corp.
View insider buying and selling activity for Zynerba Pharmaceuticals or view top insider-selling stocks.

ZYNE stock was purchased by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, AdvisorShares Investments LLC, Renaissance Technologies LLC, Penserra Capital Management LLC, Davy Global Fund Management Ltd, BlackRock Inc., JPMorgan Chase & Co., and Bank of New York Mellon Corp.
View insider buying and selling activity for Zynerba Pharmaceuticals or or view top insider-buying stocks.

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ZYNE stock can currently be purchased for approximately $4.66.

Zynerba Pharmaceuticals has a market capitalization of $137.19 million and generates $90,000.00 in revenue each year. The company earns $-32,940,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis.

Zynerba Pharmaceuticals employs 28 workers across the globe.

The official website for Zynerba Pharmaceuticals is www.zynerba.com.

Zynerba Pharmaceuticals is headquartered at 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333.

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at investorrelations[email protected]